PFE : Analysis & Opinions

  • Showing 1-100 of 167 items
  • 1
  • 2
  • >>
  1. Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst ...

    December 18, 2014
    Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
  2. Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst ...

    December 18, 2014
    Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson ...
  3. Jacobs Drives Organic Growth on Award-Winning Contract - Analyst ...

    December 17, 2014
    Jacobs Engineering Group Inc. (JEC) recently received the Facility of the Year Award (FOYA) for successfully delivering the ...
  4. OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst ...

    December 17, 2014
    OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously ...
  5. Baxter to Vend Vero Cell Vaccine Platform to Nanotherapeutics ...

    December 16, 2014
    Baxter International Inc (BAX) is set to divest its Vero cell technology and related assets to Nanotherapeutics, Inc for ...
  6. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  7. Get Ready for Shift in Fed Policy - Ahead of Wall Street

    October 28, 2014
    The Fed genuinely wants to get out of the QE business and start the monetary policy 'normalization' process.
  8. Profit From The Largest Generation In History: 2 Companies Boomers ...

    October 8, 2014
    Geo-political tensions, historic monetary programs and a global economy that has yet to show us much have all helped to quiet ...
  9. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  10. An Investing Legend Predicts A Major M&A Boom -- Here's How To ...

    August 7, 2014
    Some high-profile buyout deals have been falling apart lately. For instance, the third largest U.S. wireless carrier Sprint ...
  11. Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little blue pill.

    Why There's Far More To Pfizer Than Viagra

    July 30, 2014
    Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little ...
  12. Q3 Estimates Beginning to Slip - Ahead of Wall Street

    July 29, 2014
    Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
  13. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  14. #PreMarket Primer: Tuesday, May 27: Hope Rises In Ukraine Despite ...

    May 27, 2014
    Following the election of billionaire Petro Poroshenko as President of Ukraine, diplomatic tensions seemed to be easing ...
  15. Global Markets Indicate Weakness - Ahead of Wall Street

    May 19, 2014
    Pre-open sentiment is pointing to a weak start for U.S. stocks, with soft overnight trading action across global markets.
  16. #PreMarket Primer: Monday, May 19: DirecTV Rises On Offer From ...

    May 19, 2014
    AT&T Inc. announced a deal to acquire DirecTV for $49 billion over the weekend, as the firm attempts to adapt to a quickly ...
  17. A Big Week for Economic & Earnings Data - Ahead of Wall Street

    April 28, 2014
    The week is packed with economic and Q1 earnings reports.
  18. New Brunswick, N.J.-based Johnson & Johnson is probably most famous as the parent company of multiple household products that double as household names.

    How Johnson & Johnson Became A Household Name

    April 21, 2014
    New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household ...
  19. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  20. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  21. These Companies Know The Future Before It Happens

    February 13, 2014
    Wouldn't it be great to have a crystal ball to see into the future?You could know when the next market crash will be, ...
  22. Buybacks Instead of Capital Investment - Ahead of Wall Street

    January 28, 2014
    Hard to make sense of the fact that companies would consider it prudent to invest in their own sharesinstead of their businesses.
  23. Capital Spending vs. Buybacks - Ahead of Wall Street

    December 24, 2013
    If the Durable Goods report is a sign of things to come, then it would be a material improvement in the economic outlook.
  24. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  25. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  26. Better Margins Can't Hide Merck's Growth Challenges

    July 30, 2013
    Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
  27. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  28. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  29. Weak Earnings Growth Outside Finance - Earnings Trends

    July 25, 2013
    Weak Earnings Growth Outside Finance - Earnings Trends
  30. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  31. FDA Accepts Pfizer sNDA - Analyst Blog

    June 26, 2013
    The FDA's decision regarding the Xeljanz label expansion should be out by Feb 2014.
  32. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  33. Pfizer Gives Up Stake in Zoetis - Analyst Blog

    June 25, 2013
    Pfizer lowered its outlook for 2013 to reflect the impact of the divestment of the remaining stake in Zoetis.
  34. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  35. Ariad's Iclusig in GIST Phase II Study - Analyst Blog

    June 18, 2013
    The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor ...
  36. Make Money From Spinoffs

    June 4, 2013
    According to Barrons, 15 spinoffs have taken place in 2013 through the end of May, 50% more than last year. It seems all ...
  37. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  38. Coty Readies IPO

    May 28, 2013
    Fragrance maker Coty filed a registration statement amendment May 28 that sees it raising as much as $1.2 billion from its ...
  39. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  40. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  41. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  42. Agilent Misses, Guidance Disappoints - Analyst Blog

    February 15, 2013
    Agilent Technologies' A) fiscal first quarter earnings per share of 63 cents missed the Zacks Consensus Estimate by 4 cents, ...
  43. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  44. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  45. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  46. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  47. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  48. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space. ...
  49. Pfizer's Lyrica Scores in Study - Analyst Blog

    November 21, 2012
    Pfizer Inc. (PFE) recently announced positive top-line data on its once-daily formulation of Lyrica (pregabalin). Results ...
  50. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  51. Bayer Buys Schiff Nutrition International: Winners All Around

    November 7, 2012
    Bayer announced November 2 that it's buying Schiff for $1.2 billion to bulk up its consumer business.
  52. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  53. Pfizer's Third Quarter Earnings Report

    November 1, 2012
    Pfizer (NYSE:PFE) announced its results for the most recent quarter on November 1, 2012. Pfizer is a global pharmaceutical ...
  54. Pfizer Third Quarter Earnings Preview

    October 25, 2012
    When Pfizer (NYSE:PFE) releases its third quarter earnings on Tuesday, October 30, 2012, analysts are expecting a 16.1% drop ...
  55. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  56. Pfizer Is Near a Key Resistance Area

    September 27, 2012
    New York, September 27th (TradersHuddle.com) - Shares of Pfizer, Inc. (NYSE:PFE) are trading very close to calculated resistance ...
  57. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  58. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & ...
  59. Huntington Launches Sector Rotation ETF (HUSE)

    July 30, 2012
    Huntington, fresh off its initial foray into the ETF industry in June, has doubled the size of its lineup with the launch ...
  60. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  61. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  62. Is Pfizer Reversing?

    July 23, 2012
    New York, July 23rd (TradersHuddle.com) - Shares of Pfizer, Inc. (NYSE:PFE) closed the trading day lower by $0.1 or -0.4% ...
  63. The Most Overbought Dow Stocks

    July 3, 2012
    Despite large first-quarter gains, two big Dow stocks show strong monthly chart formations and are worthy of new buying. ...
  64. Dow 30 Stocks With High Dividends

    June 1, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  65. Wide Moat Research Vs. S&P 500

    May 11, 2012
    Comparing the performance of the Wide Moat strategy versus the S&P 500.
  66. Pfizer: Momentum Continues to Build

    May 3, 2012
    Pfizer: Momentum Continues to Build
  67. Exxon Mobil Staying Energetic

    May 2, 2012
    Exxon Mobil doesn't appear to be having any expansion problems whatsoever.
  68. The Costs Of Being Obese

    May 2, 2012
    Numbers released by the Mayo Clinic suggest obesity costs more than smoking.
  69. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America to your ...
  70. Nestle Almost Never On Sale

    April 24, 2012
    Nestle has a well-earned reputation for excellence and the Street has long been happy to pay a premium for that performance. ...
  71. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  72. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  73. Stocks For An Uncertain World

    February 29, 2012
    if you treat investments as a way to build wealth, then owning some of today's cash-rich income-producing stocks could pay ...
  74. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  75. Pfizer Shrugs Off the Loss Of Lipitor

    February 6, 2012
    Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit ...
  76. Treat Stocks Like Savings

    January 30, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  77. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  78. Slow And Steady ETFs Outperforming

    January 3, 2012
    Low volatility ETFs lead the way in 2011.
  79. The War Against Alzheimer's Requires Thinking Small

    January 2, 2012
    A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure. ...
  80. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  81. 5 Dow 30 Stocks With Huge Dividends

    November 24, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  82. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  83. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  84. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  85. High Yielding Equities

    October 21, 2011
    Despite the market volatility, there are still some stocks and ETFs that pay above-average dividend yields.
  86. PPD Goes Private

    October 6, 2011
    PPD's acceptance of a low buyout bid raises questions about the CRO industry.
  87. What Is Walgreen's Next Trick?

    September 30, 2011
    Walgreen is doing okay today, but tomorrow is a much bigger question.
  88. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  89. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
  90. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  91. 2 Oversold High-Yield Stocks

    August 11, 2011
    Two of Big Pharma’s finest are looking quite oversold at current levels, and while risk remains, both pay handsome yields ...
  92. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  93. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  94. The Best IPOs From The First Half

    July 5, 2011
    The swarm of IPO activity that has graced the market in the first half of the year has injected major league cash into some ...
  95. Top Drug Stocks

    June 30, 2011
    Recently, three strong factors are driving investors to the drug sector.
  96. Pleasure And Pain For Pfizer

    June 27, 2011
    Pfizer sees a new pain pill make it to market and another sent back to the drawing board.
  97. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  98. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  99. Lipitor: Pfizer's Loss Is Watson's Gain

    June 10, 2011
    With Lipitor coming off its patent soon, there are a couple of drug companies looking to cash in on sales of the generic ...
  100. 7 Dividend Stocks With Big Payouts

    May 4, 2011
    Dividend increases are being seen across the board. Find out which stocks are offering the biggest payouts.
  • Showing 1-100 of 167 items
  • 1
  • 2
  • >>
Trading Center